Study of Raludotatug Deruxtecan for Ovarian Cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This study tests a new drug called raludotatug deruxtecan for people with ovarian cancer that has come back. It's designed for those whose cancer is either sensitive or resistant to platinum chemotherapy, and who have had 1-3 prior treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have high-grade serous ovarian, primary peritoneal, or fallopian tube cancer that has come back.
- Your cancer can be measured on a scan (like a CT or MRI).
- If you are in a platinum-sensitive group, your cancer came back 6 months or more after your last platinum chemo, and you've had 1-3 prior treatments.
- If you are in a platinum-resistant group, your cancer came back within 6 months of your last platinum chemo, and you've had 1-3 prior treatments.
- You must be able to provide a fresh tumor sample from a biopsy.
- You are well enough to be up and about (Eastern Cooperative Oncology Group performance status 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a common chemotherapy (Pegylated Liposomal Doxorubicin) plus an immunotherapy (Adebrelimab), with or without a bladder medication (Mirabegron), in people whose ovarian cancer has returned after initial treatment. The goal is to see if adding Mirabegron helps the other drugs work better.
This study tests a new drug (raludotatug deruxtecan) with or without another drug (bevacizumab) as maintenance therapy after initial chemotherapy for advanced ovarian cancer. It aims to see if this combination can help keep the cancer from coming back.
This study tests a new drug called Raludotatug Deruxtecan (R-DXd) for people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if R-DXd can shrink tumors or slow cancer growth.
This study tests a new drug, Raludotatug Deruxtecan (R-DXd), given alone or with another drug called bevacizumab, as ongoing treatment after initial chemotherapy for recurrent ovarian cancer. It aims to see if this maintenance treatment helps keep the cancer from coming back longer.
This trial tests a new drug called mocertatug rezetecan combined with bevacizumab against standard platinum chemo plus bevacizumab. It's for women with ovarian cancer that came back after treatment and is still sensitive to platinum drugs.
This trial compares a targeted drug called trastuzumab deruxtecan to standard treatment for ovarian, fallopian tube, or primary peritoneal cancer that has come back after previous treatment with a PARP inhibitor. The study is for patients whose tumors show a certain level of a protein called HER2 on their surface.
Hear when a new Ovarian Cancer Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.